Status note First clinical product of the ExacTcell T-cell platform. Completed a Phase 1 proof-of-concept clinical trial for ambulatory, high-risk adult COVID-19 patients. The Company states its business is highly dependent on TVGN 489.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.